BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 12765773)

  • 1. Evolving views in prion glycosylation: functional and pathological implications.
    Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
    Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.
    Marshall KE; Hughson A; Vascellari S; Priola SA; Sakudo A; Onodera T; Baron GS
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27847358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proportions of C1 truncated prion protein protect against cellular M1000 prion infection.
    Lewis V; Hill AF; Haigh CL; Klug GM; Masters CL; Lawson VA; Collins SJ
    J Neuropathol Exp Neurol; 2009 Oct; 68(10):1125-35. PubMed ID: 19918124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
    Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
    J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prion protein and lipid rafts.
    Taylor DR; Hooper NM
    Mol Membr Biol; 2006; 23(1):89-99. PubMed ID: 16611584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialylation of the prion protein glycans controls prion replication rate and glycoform ratio.
    Katorcha E; Makarava N; Savtchenko R; Baskakov IV
    Sci Rep; 2015 Nov; 5():16912. PubMed ID: 26576925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species barrier in prion diseases: a kinetic interpretation based on the conformational adaptation of the prion protein.
    Kellershohn N; Laurent M
    Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):539-45. PubMed ID: 9729459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
    Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
    Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.
    Taylor DR; Whitehouse IJ; Hooper NM
    PLoS Pathog; 2009 Nov; 5(11):e1000666. PubMed ID: 19936054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.
    Phuan PW; Zorn JA; Safar J; Giles K; Prusiner SB; Cohen FE; May BCH
    J Gen Virol; 2007 Apr; 88(Pt 4):1392-1401. PubMed ID: 17374787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into prion structure and toxicity.
    Harris DA; True HL
    Neuron; 2006 May; 50(3):353-7. PubMed ID: 16675391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion channel proteins and their role in vacuolation and neurodegenerative diseases.
    Kourie JI
    Eur Biophys J; 2002 Sep; 31(5):409-16. PubMed ID: 12202918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion protein functions and dysfunction in prion diseases.
    Sakudo A; Ikuta K
    Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion protein-Semisynthetic prion protein (PrP) variants with posttranslational modifications.
    Hackl S; Becker CFW
    J Pept Sci; 2019 Oct; 25(10):e3216. PubMed ID: 31713950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.
    Pan T; Wong P; Chang B; Li C; Li R; Kang SC; Wisniewski T; Sy MS
    J Virol; 2005 Jan; 79(2):934-43. PubMed ID: 15613322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The state of the prion.
    Weissmann C
    Nat Rev Microbiol; 2004 Nov; 2(11):861-71. PubMed ID: 15494743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prion protein and metal interaction: physiological and pathological implications.
    Singh N; Das D; Singh A; Mohan ML
    Curr Issues Mol Biol; 2010; 12(2):99-107. PubMed ID: 19767653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.